Akhil Santhosh

Akhil Santhosh

Auto-generated profile, based on publicly available information

Akhil Santhosh

Department of Medical Oncology, MVR Cancer Centre and Research Institute, Calicut, Kerala, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ASAkhil Santhosh
Akhil Santhosh
ASAtul Sharma
Atul Sharma
SBSameer Bakhshi
Sameer Bakhshi
AKAkash Kumar
Akash Kumar
VSVinod Sharma
Vinod Sharma
OIon behalf of the D-TORCH Trial Investigators
on behalf of the D-TORCH Trial Investigators
PURPOSE: Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated inflammation. However, systemic side effects of celecoxib have limited routine prescription. Topical diclofenac inhibits COX-2 locally with minimal risk of systemic adverse events. Therefore, we conducted this study to assess the efficacy of topical diclofenac in the prevention of capecitabine-induced HFS. METHODS: In this single-site phase III randomized double-blind trial, we enrolled patients with breast or GI cancer who were planned to receive capecitabine-based treatment. Participants were randomly assigned in a 1:1 ratio to receive topical diclofenac or placebo gel for 12 weeks or until the development of HFS, whichever occurred earlier. The primary end point was the incidence of grade 2 or 3 HFS (Common Terminology Criteria for Adverse Events version 5), which was compared between the two groups using simple logistic regression. RESULTS: In total, 264 patients were randomly assigned to receive topical diclofenac gel (n = 131) or placebo (n = 133). Grade 2 or 3 HFS was observed in 3.8% of participants in the diclofenac group compared with 15.0% in the placebo group (absolute difference, 11.2%; 95% CI, 4.3 to 18.1; P = .003). Grade 1-3 HFS was lower in the diclofenac group than in the placebo group (6.1% v 18.1%; absolute risk difference, 11.9%; 95% CI, 4.1 to 19.6). Capecitabine dose reductions because of HFS were less frequent in the diclofenac group (3.8%) than in the placebo group (13.5%; absolute risk difference, 9.7%; 95% CI, 3.0 to 16.4). CONCLUSION: Topical diclofenac prevented HFS in patients receiving capecitabine. This trial supports the use of topical diclofenac to prevent capecitabine-associated HFS.

30 April 2025 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
PDF file
ASAkhil Santhosh
Akhil Santhosh
We read the TULIP trial by Turner et al[1] that tested the role of trastuzumab duocarmazine (T-Duo) in recurrent HER2+ metastatic breast cancer. T-Duo (SYD 985) is a novel next-generation HER2-targeted antibody-drug conjugate (ADC) with a cleavable payload (vc-seco-DUBA) conjugated with trastuzumab. In this phase 3 open-label, randomized controlled trial, patients aged ≥ 18 years were randomized (in 2:1 ratio) to receive T-Duo or physician's choice (PC) therapy (lapatinib–capecitabine, capecitabine–trastuzumab, trastuzumab–vinorelbine, or trastuzumab–eribulin). Patients received a median of three prior lines of anti-HER2 therapies; of which 60.8 and 57.5% patients received pertuzumab and 2.1 and 1.4% patients received trastuzumab deruxtecan (T-DXd) in the experimental and control arms, respectively. The study met its primary endpoint of progression-free survival (PFS) prolongation in the T-Duo arm with a median PFS of 7 months (95% confidence interval [CI], 5.4–7.2) versus 4.9 months (95% CI, 4.0N5.5) for PC therapy. The overall response rate by central imaging review was 27.8% in the T-Duo arm versus 29.5% in the PC arm. The median duration of response was 15.1 months (95% CI, 5.7–15.1) for T-Duo versus 4.6 months (95% CI, 2.8–7.1) for PC. Overall survival results are currently immature. Ocular adverse events were notable with T-Duo (78.1% any grade, 21.2% grade 3). The incidence of interstitial lung disease and pneumonitis were similar to that seen with other anti-HER 2 ADCs like ado-trastuzumab emtansine (TDM1) and T-DXd. It is imperative that we understand that by the time this trial accrued, tremendous progress was already made in HER2-positive metastatic breast cancer space. Initially tested in third line and beyond in the DESTINY 02 trial[2] with impressive results, T-DXd went on to trump TDM1 in the subsequent DESTINY 03 study[3] and is currently the favored drug in the second-line therapy. Impressive central nervous system (CNS) response rates of 73.3 and 46.2% were received from the TUXEDO-1[4] and DEBBRAH[5] trials, respectively. Therefore, the activity of T-DXd supersedes any other anti-HER2 therapy. Hardly 2% of patients in TULIP received T-DXd and responses post-T-DXd with T-Duo are not known. The brain is a notable sanctuary site for recurrent HER2+ disease and up to 50% of patients develop brain metastases.[6] TULIP does not give us any idea regarding the intracranial efficacy of T-Duo. The hazard ratio for patients with brain metastases is not impressive, albeit this could be explained by the small patient population. Every patient with advanced cancer needs to live longer and live better. With 78% of ocular adverse events (20% grade 3 or more), T-Duo unfortunately cuts a sorry figure and hampers the coveted parameter of “quality of life.” Despite the use of prophylactic eye drops and regular ophthalmological examinations (slit lamp exam, corneal sensitivity testing, fluorescence tear film break-up time, and pachymetry), these adverse events could not be prevented. Also, they persisted for months and were slow to recover, unlike the case with some ADCs like tisotumab vedotin, where strict prophylaxis and timely dose modifications helped.[7] Duocarmazine payloads have an inherent risk of cardiotoxicity. In the dose-expansion study of T-Duo, reversible left ventricular dysfunction was reported in 11 patients (7% grade 1–2, 1% grade 3).[8] Readers are deprived of the same data in TULIP. The performance of an ADC depends upon four factors, namely, the stability of the linker molecule in plasma, activity and toxicity profile of the cytotoxic moiety, drug-to-antibody ratio (DAR), and membrane permeability. For T-Duo, the poor DAR (2.8:1) is compensated by the presence of a cleavable linker and a bystander effect, unlike TDM1. Nevertheless, all is not gloomy for this late entrant. The median PFS of 7 months in TULIP augurs well with the TH3RESA[9] and HER2CLIMB[10] data with TDM1 and tucatinib, respectively. Tucatinib scores above these two drugs in its ability to elicit good CNS control. T-DXd is almost being front-lined into the management of HER2-positive metastatic breast cancer and the DESTINY BREAST 09 results will be released soon. Hence, there is a huge scope of potential for new drugs as second and subsequent options in the therapeutic armamentarium of HER2-positive breast cancer. The low incidence of myelosuppression and nausea/vomiting with T-Duo makes it an ideal option to combine with other drugs. TDM1 is already being revived in this manner through the HER2CLIMB02[11] and CompassHER2RD trials, where it is combined with tucatinib in the metastatic and post-neoadjuvant-residual disease settings, respectively. ADC resistance may arise from defective internalization and trafficking pathways. Small molecules like tucatinib and neratinib are known to stabilize HER2 on the cell membrane facilitating the action of ADCs. Also, studies are underway combining T-Duo with poly(ADP-ribose) polymerase (PARP) inhibitors in locally advanced or metastatic solid tumors expressing HER2.[12] The rationale behind this strategy is the synthetic lethality offered by the alkylator payload and PARP inhibitors. Another possible avenue is the combination of immune checkpoint inhibitors with ADCs. ADCs are known to enhance antigen presentation through antibody-dependent cellular toxicity and increase the CD8+ flux into the tumor microenvironment. This was evident from the arm 6 of the BEGONIA trial where durvalumab + T-DXd elicited an overall response rate of 66.7%.[13] Lastly, an area where T-Duo can work wonders like T-DXd is the HER2-low subset of breast cancer. In the phase 1 study, 9/32 (28%) patients with HER2-low/HR+ and 6/15 (40%) patients with HER2-low/HR− patients had confirmed RECIST (Response Evaluation Criteria in Solid Tumors) responses.[6] T-Duo is also being tested in other HER2-positive metastatic...

18 March 2026 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
PDF file
DSDr Nihanthy D S
Dr Nihanthy D S
ASAkhil Santhosh
Akhil Santhosh
There is a hush between naming a disease and letting someone go—a space too quiet for science, too sacred for metrics. In that flickering gap where knowledge reaches its limit, and love begins to listen; we often find ourselves. Not in clinical guidelines or Kaplan–Meier curves, but in the tremble of a hand, the silence between sobs, the dreams that unravel without fanfare. That is where we met Maya. She came to us on a monsoon evening. The sky was dark, and the air hung heavy with rain and something else. Something unnamed. Maya was just thirty. Metastatic breast cancer had already made a home of her body, uninvited and unrelenting. Her prognosis was written in cold lines and percentages, but she arrived with warmth that defied them. She wore bright scarves; crimson, marigold, turquoise—like little rebellions tied around her head. “If I must lose my hair,” she smiled, “let me at least wear a little sunshine.” Maya had once dreamt of becoming a baker. Not a celebrity chef, not a patisserie connoisseur just someone who could open a little bakery tucked into a quiet street where the smell of cardamom buns and mango tarts would spill into the morning air. She believed in the alchemy of sugar and sorrow. “There's something holy,” she once said, “In the way heat and sweetness can soften grief.” For Maya, baking was sacred. Memory kneaded into dough. Love poured into molds. Healing—slow, deliberate, one slice at a time. She had been saving for pastry school in Paris. But cancer is ravenous, it devours more than just the body. It takes not just health, but hope. Not just time, but timelines. Her savings disappeared into travel, consultations, scans. The dream stayed folded inside a drawer she would never reopen. We rarely spoke in numbers. Instead, we talked of quieter things—poems, pastries, the smell of summers past, and the mango tree that grew wild behind her childhood home. Her questions were never about dying. They were about time: “Will I be well enough to bake my brother's birthday cake?” “Do you think I'll still be here when the jacarandas bloom?” As her body thinned, her spirit expanded. She grew more luminous as she grew weaker, fiercely tender even as her strength drained away. She didn't fight the cancer; she made room for it. Not with surrender, but with grace. With eyes wide open and an aching kind of joy. She wove life around it. Fierce in fragility. And then, one day, she broke. She had just returned from a draining chemo session, hands shaking from fatigue. Her voice was small, almost not there. “I've never said this before,” she whispered, “but I lost both my parents in a car accident; years ago. I raised my younger brother after that. He's just twenty now. He doesn't show it, but I know he's scared. He's all I have. I'm all he has. What happens to him… when I go?” And in that moment, the room felt too small for the weight of her grief. It was the kind of pain no medication could touch, grief not just for her life, but for the life she wouldn't get to protect. Her fear wasn't death but it was abandonment. Of a boy she had mothered in her own mourning. Of a dream she had carried through too much loss already. Even as her body failed her, she held on to care, to kinship, to crumbs of love she kept leaving behind, hoping they'd be enough to lead her brother forward. Between chemo cycles, she would sometimes bring us peach muffins, lemon madeleines—baked in the windows of strength between nausea and fatigue. Her hands had started to tremble. Her fingertips bore the bruises of countless intravenous lines. But still, she stirred, she poured, and she baked. Each bite was defiance. Each dessert a quiet, quivering stand against despair. “I may never own that bakery,” she once whispered, “but I've baked more love into the world than most get to in a lifetime.” And it was true. There was such aching in her acceptance. Not resignation but a quiet, sacred grace. A recognition that life had not been fair, but she could still make something beautiful out of what remained. A kind of luminous surrender that isn't about giving up, but about giving in to what is, and still choosing beauty. In Maya, we saw a kind of courage that doesn't roar nor makes headlines. It stirs quietly in a steel bowl. It rises slowly in a warm oven. It shows up in soft-spoken sisters who shoulder entire families. In women who do not get the future they deserve, but still insist on loving what little is left. Her story is not rare. It echoes across clinics and countries; where dreams are interrupted not just by disease but by disparities. Where women like Maya don't just fight cancer; they fight for dignity, for access, and for the right to dream beyond diagnosis. And as the 21st century unfolds with artificial intelligence and molecular magic, with targeted therapies and genomic marvels; we must not forget the trembling, tender heart of medicine. The heart of healing lies not just in intervention, but in presence. To hold a hand. To wait in silence. To ask, not only “What hurts?” but “What matters?” To honor not just the science of cure, but the art of care. Maya left on a gray, rain-washed afternoon, as quietly as she had lived. Months after Maya was gone, her younger brother came to visit us. He arrived quietly and shoulders curved with a grief too heavy for someone so young. He had been just a child; barely six years old when they lost their parents. Too young to remember the exact texture of his mother's voice, but old enough to remember how Maya stepped in, arms barely grown, and became everything: mother, sister, shelter, and light. “I don't remember Amma much,” he whispered, “but I remember Maya, flour on her face, kneading dough with all the love she didn't know how to say.” What we hadn't known was...

5 May 2025 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
PDF file
ASAkhil Santhosh
Akhil Santhosh
The initial progression-free survival (PFS) results of PRIMA were published before, with niraparib substantially prolonging PFS in patients with newly diagnosed advanced ovarian cancer regardless of homologous recombination deficiency (HRD) status.[1] The final overall survival (OS) results were published in the September 2024 edition of Annals of Oncology showing no difference in OS between niraparib and placebo.[2] The entire oncology fraternity was inquisitive as to what went wrong with some even questioning the inferiority of niraparib compared with other poly ADP-ribose polymerase (PARP) inhibitors. Nevertheless, given the similarity in PFS across PRIMA, SOLO-1, and PAOLA-1, this seems unlikely. The majority of enrollment in PRIMA and PAOLA-1 was done from Europe and North America with minimal representation of Asians; hence, the difference in ethnicity cannot be accounted for the difference in outcomes. Additionally, there is no significant difference between olaparib, rucaparib, and niraparib in terms of PARP-trapping efficacy in preclinical models. Regarding disease burden, both the SOLO-1 and PAOLA-1 trials[3] with olaparib and olaparib/bevacizumab, respectively, in an upfront maintenance setting had relatively lower disease burden patients compared with PRIMA, which consisted of higher-risk patients (66.7% patients required neoadjuvant chemotherapy). PRIMA excluded stage III patients who underwent R0 resection in contrast to SOLO-1, which included only BRCA mutated disease (favorable subset). The percentage of patients with residual disease postsurgery or no surgery was higher in the niraparib study.[1] Also, the results from all the prespecified subgroups should be interpreted with caution given the small sample size (especially the HRD neg/BRCA wild-type subset). PRIMA was not powered to detect an OS benefit in these subgroups. Therefore, the future does not look promising for niraparib, which is a 3-year therapy, in comparison to olaparib (2 years) as maintenance. Niraparib is also poorly tolerated compared to olaparib with treatment interruptions, dose reductions, and discontinuations occurring in 80.8, 71.7, and16.3%, respectively, for niraparib compared with 52, 28, and 12% patients, respectively, with olaparib in SOLO-1.[4] This issue has been abrogated to an extent with the PRIME trial showing that patients taking an individualized starting dose (patients with ≤ 77 kg, platelet count < 150,000 receiving 200 mg once daily [OD], with the remaining receiving 300 mg OD) had better tolerance with an acceptable safety profile.[5] This dosing pattern was followed only for 35% of patients in PRIMA. Access to olaparib in middle- and lower middle-income countries has improved over the past few years with introduction of various patient assistance programs. Clinicians worldwide are more comfortable and adept in prescribing and managing toxicities with olaparib compared to the other drugs in the same category. Unfortunately, the U.S. Food and Drug Administration approval is no longer valid for second-line indications of niraparib in non-BRCA mutated disease.[6] Hence, it is nonfeasible to consider this drug for the contemporary management of advanced ovarian cancer. Results of trials in progress like NIRVANA-1[7] and AGO-OVAR 28[8] for evaluating maintenance therapy with niraparib and bevacizumab combined seem to be favorable and would throw some light on how to better use niraparib in the future. Article published online: 05 May 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

1 July 2025 in Indian Journal of Cancer
Verified
Journal Article
Open access
ASAkhil P Santhosh
Akhil P Santhosh
SRSAMEER RASTOGI
SAMEER RASTOGI
SSShamim Ahmed Shamim
Shamim Ahmed Shamim
RYRajni Yadav
Rajni Yadav
DKDikhra Khan
Dikhra Khan
Background: Succinate dehydrogenase (SDH) deficient gastrointestinal stromal tumor (GIST) is the most common type of wild type GIST characterized by lack of mutations in proto-oncogene receptor tyrosine kinase (KIT) or platelet-derived growth factor receptor alpha (PDFGR alpha) pathways. It has a unique predilection for females and young adults, with a relatively indolent prognosis and varied treatment modalities. Data regarding SDH GIST from the Indian subcontinent is sparse. Materials and Methods: This is a retrospective study of patients with SDH deficient GIST, who presented to the GIST clinic in a tertiary care center in India from 2016–2022. 9 out of 120 GIST patients were SDH deficient. All patients were discussed in GIST tumor board and pathologies were re-reviewed by a dedicated GIST pathologist. Data was collected retrospectively from prospectively maintained database. Results: There were nine patients with median age of 48 years (range 15–63), of which there were 5 males ( n = 5, 55.5%). Eight patients ( n = 8, 88.8%) had primary in stomach, one had duodenal GIST. In stomach, body was the most common location ( n = 6,75%). 3 out of 9 patients ( n = 3, 33.3%) had multifocal disease. 8 out of 9 (88.8%) had metastasis at presentation. Most common site of metastasis was liver (7 out of 8, 87.5%) Lymph node involvement was present in 4 out of 9 patients (44.4%). One patient had classical Carneys triad at presentation. 8 out of 9 (88.8%) had epithelioid morphology and 1 (11.1%) had mixed epithelioid-spindle picture. 5 out of 9 (55.5%) patients had germline SDH mutations. Out of nine patients, one was put on observation post surgery and therapy was given for eight patients ( n = 8,88.8%). Response to imatinib was very poor, 3 out of 5 patients (60%) had response with sunitinib, three were started on regorafenib out of which one had partial response and one patient had partial response with temozolomide. Median overall survival was NR- not reached (95% CI 12.96-NR). Conclusion: SDH deficient GIST is a unique subtype of gastrointestinal stromal tumor with distinct clinic-pathological features, diagnostic modalities, therapeutic strategies, and genetic implications as compared to C-kit/PDGFR-alpha mutated GIST.

4 May 2026 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
DSDr Nihanthy D S
Dr Nihanthy D S
ASAkhil Santhosh
Akhil Santhosh